Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 90Recruiting 83Completed 22Not yet recruiting 15Terminated 5Suspended 2Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 3Lymphoid 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 3Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Burkitt Lymphoma 1

Interventions

pembrolizumab 28Carboplatin 18Cisplatin 15Nivolumab 13Pemetrexed 12Paclitaxel 11Specimen Handling 10Ipilimumab 10Gemcitabine 10venetoclax 8durvalumab 8atezolizumab 8Radiotherapy 8Radiosurgery 8Magnetic Resonance Spectroscopy 8Docetaxel 7Cyclophosphamide 7Biopsy 7fludarabine 6enzalutamide 6Bevacizumab 6tislelizumab 5tazemetostat 5X-Rays 5Trastuzumab 5Surveys and Questionnaires 5Practice Guidelines as Topic 5Interviews as Topic 5Injections 5Dexamethasone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × Dexamethasone × 90 days × Clear all
NCT03808610 2026-05-13

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Terminated
53 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03173092 2026-05-04

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Takeda

Phase 4 Terminated
141 enrolled
Plasma cell

Multiple Myeloma

NCT05090566 2026-04-24

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Pfizer

Phase 2 Terminated
46 enrolled 15 charts
Plasma cell

Multiple Myeloma

NCT06163898 2026-04-21

A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

Celgene

Phase 1 Terminated
4 enrolled
Plasma cell

Multiple Myeloma

NCT05498220 2026-04-16

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Terminated
5 enrolled 13 charts
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡